TY - JOUR
T1 - Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy
AU - Bond, David A.
AU - Switchenko, Jeffrey M.
AU - Villa, Diego
AU - Maddocks, Kami
AU - Churnetski, Michael
AU - Gerrie, Alina S.
AU - Goyal, Subir
AU - Shanmugasundaram, Krithika
AU - Calzada, Oscar
AU - Kolla, Bhaskar
AU - Bachanova, Veronika
AU - Gerson, James N.
AU - Barta, Stefan K.
AU - Hill, Brian T.
AU - Sawalha, Yazeed
AU - Martin, Peter
AU - Maldonado, Edward
AU - Gordon, Max
AU - Danilov, Alexey V.
AU - Grover, Natalie S.
AU - Mathews, Stephanie
AU - Burkart, Madelyn
AU - Karmali, Reem
AU - Ghosh, Nilanjan
AU - Park, Steven I.
AU - Epperla, Narendranath
AU - Badar, Talha
AU - Guo, Jin
AU - Hamadani, Mehdi
AU - Fenske, Timothy S.
AU - Malecek, Mary Kate
AU - Kahl, Brad S.
AU - Flowers, Christopher R.
AU - Blum, Kristie A.
AU - Cohen, Jonathon B.
N1 - Publisher Copyright:
© 2021 by The American Society of Hematology.
PY - 2021/12/14
Y1 - 2021/12/14
N2 - Although an expanding array of effective treatments has resulted in recent improvement in survival of patients with mantle cell lymphoma (MCL), outcomes remain heterogeneous, and identification of prognostic factors remains a priority. We assessed the prognostic impact of time to progression of disease (POD) afterfirst-line therapy among455 patients with relapsed MCL. Patients were categorized by duration of first remission as PRF/POD6, defined as progressive diseaseduringinduction orPODwithin6monthsof diagnosis (n565;14%);POD6-24, definedasPODbetween 6and24months after diagnosis (n5153; 34%);andPOD.24, defined asPOD.24monthsafterdiagnosis(n5237;53%).ThemedianoverallsurvivalfromPOD(OS2) was 1.3 years (95%confidence interval [CI], 0.9-2.4) for patients with PRF/POD6, 3 years (95% CI, 2-6.8) for those with POD6-24, and 8 years (95%CI, 6.2-NR) for those withPOD.24. Median OS2 was inferior in patients with early POD (defined as PRF/POD6 or POD6-24) after both intensive and less intensive frontline treatment. The prognostic performance of time until PODwasreplicated inanindependent cohort of 245 patients with relapsedMCL,withmedian OS2 of 0.3 years (95%CI, 0.1-0.5) for PRF/POD6, 0.8 years (95%CI, 0.6-0.9) for POD6-24, and 2.4 years (95%CI 2.1-2.7) for POD.24. Early POD is associated with inferior OS2 in patients with relapsed MCL, identifying a high-risk population for future prospective studies.
AB - Although an expanding array of effective treatments has resulted in recent improvement in survival of patients with mantle cell lymphoma (MCL), outcomes remain heterogeneous, and identification of prognostic factors remains a priority. We assessed the prognostic impact of time to progression of disease (POD) afterfirst-line therapy among455 patients with relapsed MCL. Patients were categorized by duration of first remission as PRF/POD6, defined as progressive diseaseduringinduction orPODwithin6monthsof diagnosis (n565;14%);POD6-24, definedasPODbetween 6and24months after diagnosis (n5153; 34%);andPOD.24, defined asPOD.24monthsafterdiagnosis(n5237;53%).ThemedianoverallsurvivalfromPOD(OS2) was 1.3 years (95%confidence interval [CI], 0.9-2.4) for patients with PRF/POD6, 3 years (95% CI, 2-6.8) for those with POD6-24, and 8 years (95%CI, 6.2-NR) for those withPOD.24. Median OS2 was inferior in patients with early POD (defined as PRF/POD6 or POD6-24) after both intensive and less intensive frontline treatment. The prognostic performance of time until PODwasreplicated inanindependent cohort of 245 patients with relapsedMCL,withmedian OS2 of 0.3 years (95%CI, 0.1-0.5) for PRF/POD6, 0.8 years (95%CI, 0.6-0.9) for POD6-24, and 2.4 years (95%CI 2.1-2.7) for POD.24. Early POD is associated with inferior OS2 in patients with relapsed MCL, identifying a high-risk population for future prospective studies.
UR - http://www.scopus.com/inward/record.url?scp=85120335416&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2021004765
DO - 10.1182/bloodadvances.2021004765
M3 - Article
C2 - 34516611
AN - SCOPUS:85120335416
SN - 2473-9529
VL - 5
SP - 5179
EP - 5189
JO - Blood Advances
JF - Blood Advances
ER -